EDDA Technology, a provider of advanced imaging-guided precision treatment solutions, announced it has entered into an agreement with the Society of Interventional Oncology (SIO) for its ACCLAIM Trial (Ablation with Confirmation of Colorectal Liver Metastases Prospective Trial for Microwave Ablation as a Local Cure). IQQA-BodyImaging Interventional will be used to provide 3D assessment of the ablation zone and margin for selected colorectal liver metastases.
In this prospective, multicentre, international trial, SIO proposes to establish microwave ablation (MWA) as the preferred treatment option for selected colorectal liver metastases that can be ablated with sufficient margins. The study will be the first global, prospective trial to use an objective and reproducible technical outcome in its study design, which the SIO believes will drive important changes to future treatment guidelines. The ACCLAIM study will estimate disease-free survival of colorectal liver metastases treated with MWA incorporating 3D ablation software (EDDA Technology) margin confirmation intraoperatively and through a subsequent independent review centralised validation process.
The IQQA platform provides comprehensive 3D image analysis using magnetic resonance (MR) and computed tomography (CT), and has been used in over 80,000 cases worldwide for surgery and treatment with substantial time-saving. This solution supports in-depth quantitative volumetry with fast, dependable results and allows for versatility of transplantation, resection, or interventional procedure planning.
“IQQA is a proven innovation to support physicians in providing individualised and optimised treatment solution. Powered by our precision 3D capabilities, IQQA aims to facilitate the next generation of precision surgery and treatment,” said Jianzhong Qian, president and CEO of EDDA Technology. “We’re glad that the IQQA platform was chosen by SIO for this global trial, which will bring important clinical information for the future interventional treatment guidelines.”